Teva Pharmaceutical Industries (NYSE:TEVA)

Big Pharma Sees Rising Tide in Short Interest

Pharmaceutical companies usually are involved in a lengthy process of getting their drug candidates to market through clinical trials. There is a fair amount of risk involved, should a study ...
Read Full Story »

Unusual Settlement Deal Proposed for Opioid Lawsuits

Five pharmaceuticals makers are proposing an unusual method for settling hundreds of the more than 2,500 lawsuits facing drugmakers that made and sold opioid painkillers. The five companies want to ...
Read Full Story »

Top Analyst Upgrades and Downgrades: Apple, Bed Bath & Beyond, Chico’s, Clorox, Deere, Gap, Newell, RealReal, Teva, UnitedHealth, Wells Fargo and More

Stocks saw many ups and downs but ended last week slightly lower, but they were indicated to open higher on Monday. This is the last day of the third quarter ...
Read Full Story »

Short Sellers Grow More Selective in Big Pharma

Pharmaceutical companies usually are involved in a lengthy process of getting their drug candidates to market through clinical trials. There is a fair amount of risk involved, should a study ...
Read Full Story »

Short Sellers Can’t Make Up Their Minds on Big Pharma

Pharmaceutical companies usually are involved in a lengthy process of getting their drug candidates to market through clinical trials. There is a fair amount of risk involved, should a study ...
Read Full Story »

Opioid Verdict: A Possible Victory for Johnson & Johnson and Loss for Everyone Else?

When companies run into legal issues in which they face potentially endless numbers of trials in numerous venues in America, it can create a tough time managing them. Johnson & ...
Read Full Story »

Big Pharma Sees a Rising Tide in Short Interest

Pharmaceutical companies usually are involved in a lengthy process of getting their drug candidates to market through clinical trials. There is a fair amount of risk involved, should a study ...
Read Full Story »

Major Pharma Sees Rising Tide in Short Interest

Pharmaceutical companies usually are involved in a lengthy process of getting their drug candidates to market through clinical trials. There is a fair amount of risk involved, should a study ...
Read Full Story »

Short Sellers Up the Ante in Big Pharma

Pharmaceutical companies usually are involved in a lengthy process of getting their drug candidates to market through clinical trials. There is a fair amount of risk involved, should a study ...
Read Full Story »

Top Analyst Upgrades and Downgrades: Agilent, Amazon, American Water Works, Crocs, Deere, GE, Gilead, Slack, Teva and More

Stocks were indicated to open marginally higher on Monday, with the indexes effectively at all-time highs based on communication from Federal Reserve Chair Jerome Powell that the agency is expected ...
Read Full Story »

Big Pharma Sees Rising Tide in Short Interest

Pharmaceutical companies usually are involved in a lengthy process of getting their drug candidates to market through clinical trials. There is a fair amount of risk involved, should a study ...
Read Full Story »

5 Sizzling New Stocks Under $10 With Massive Implied Upside

While most of Wall Street focuses on large and mega cap stocks, as they provide a degree of safety and liquidity, many investors are limited in the number of ...
Read Full Story »

Short Sellers Seek Direction on Big Pharma

Pharmaceutical companies usually are involved in a lengthy process of getting their drug candidates to market through clinical trials. There is a fair amount of risk involved, should a study ...
Read Full Story »

Big Pharma Sees a Rising Tide in Short Interest

Pharmaceutical companies usually are involved in a lengthy process of getting their drug candidates to market through clinical trials. There is a fair amount of risk involved, should a study ...
Read Full Story »

Top Analyst Upgrades and Downgrades: Agilent, Allergan, Beyond Meat, Canopy Growth, Dollar Tree, Facebook, Luckin Coffee, Lyft, Mylan, Symantec, Tilray, Wells Fargo and More

Stocks were indicated to open higher yet again on Tuesday, as June has turned into a complete role reversal from May's "sell in May" theme that was winning. Investors need ...
Read Full Story »